Global Biologics Market Size, Trends, and Growth Opportunity, By Source (Microbial, Mammalian, Others), By Product (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, Others), By Disease Category (Oncology, Infectious Diseases, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others), By Manufacturing (Outsourced, In-house), By Region and Forecast till 2030.
Global Biologics Market
The Global Biologics Market was valued at USD 350.19 billion in 2022 and is expected to expand to USD 499.21 billion in 2030 at a CAGR of 4.53 % during the forecast period 2023-2030.
Biologics are isolated from a variety of natural sources - human, animal, or microorganism and may be produced by biotechnology methods and other cutting-edge technologies. Biologics includes vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins.
Market Drivers
The increasing incidences of chronic diseases, growing government support, and rising availability of advanced diagnostics propel the growth of the market.
The growing efficacy of oral products for rheumatoid arthritis, Crohn's disease, and cancer increases the demand for biologicals and new treatments act as major factors for the growing market during the forecast period. Furthermore, the development in the productivity of biological products boosts the expansion of the market.
Market Restraints
The high cost of biologicals hinders the growth of the market. Furthermore, the lack of awareness regarding biologics restrains the growth of the global Biologics market.
COVID-19 Impact on Biologics Market
The outbreak of covid-19 adversely impacted the market as the lockdown and restrictions were imposed by the government to protect public health, and production was disrupted. Additionally, a decrease in demand for biologicals hampers the market during a pandemic.
Impact of Russia Ukraine War on the Market
The conflict between Russia and Ukraine can have both direct and indirect impacts on the biologics market:
Disruptions in the supply chain: Many biologics manufacturers source components from Russia and Ukraine. The war may cause supply chain disruptions and delays, affecting biologics production and delivery.
Economic sanctions: Economic sanctions imposed on Russia may have an impact on the overall economy, as well as the demand for biologics in the region.
Market Segmentation
The Global Biologics Market is segmented on the basis of Source, Product, Disease Category, Manufacturing, and Region. Based on the Source, it is segmented into Microbial, Mammalian, and Others. Based on the Product, it is segmented into Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others. Based on the Disease Category, is segmented into Oncology, Infectious Diseases, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others. On the basis of Manufacturing, it is segmented into Outsourced, In-house.
Regional Analysis
North America is likely to dominate the market over the forecast period owing to the growing biologic development coupled with the presence of FDA-approved biologics in this region.
Europe is also anticipated to witness substantial growth because of the rising advancement in the manufacturing sector and the availability of multiple approved drugs in this region.
Key Players
Various key players are listed in this report such as Eli Lilly & Company, Samsung Biologics, F Hoffman La Roche, Celltrion, Addgene, Amgen, Abbvie Inc, Sanofi, Pfizer Inc, Merck & Co Inc, Novo Nordisk A/S, Johnson & Johnson Services Inc.
Market Taxonomy
By Source
• Microbial
• Mammalian
• Others
By Product
• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense, RNAi, Molecular Therapy
• Others
By Disease Category
• Oncology
• Infectious Diseases
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others
By Manufacturing
• Outsourced
• In-house
By Region
• North America
• The U.S.
• Canada
• Mexico
• Latin America
• Brazil
• Malaysia
• Colombia
• Peru
• Chile
• Venezuela
• Rest of Latin America
• Europe
• Germany
• France
• UK
• Russia
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• New Zealand
• Singapore
• Malaysia
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Venezuela
Key Question Addressed by the Report
• What are the Key Opportunities in Global Biologics Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have the highest growth?
• What are the factors that will impact/drive the Market?
• What is the role of key players in the value chain?
Global Biologics Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Biologics Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Biologics Market, By Source
5.1 Y-o-Y Growth Comparison, By Source
5.2 Global Biologics Market Share Analysis, By Source
5.3 Global Biologics Market Size and Forecast, By Source
5.3.1 Microbial
5.3.2 Mammalian
5.3.3 Others
6 Global Biologics Market, By Product
6.1 Y-o-Y Growth Comparison, By Product
6.2 Global Biologics Market Share Analysis, By Product
6.3 Global Biologics Market Size and Forecast, By Product
6.3.1 Monoclonal Antibodies
6.3.2 Vaccines
6.3.3 Recombinant Proteins
6.3.4 Antisense, RNAi, Molecular Therapy
6.3.5 Others
7 Global Biologics Market, By Disease Category
7.1 Y-o-Y Growth Comparison, By Disease Category
7.2 Global Biologics Market Share Analysis, By Disease Category
7.3 Global Biologics Market Size and Forecast, By Disease Category
7.3.1 Oncology
7.3.2 Infectious Diseases
7.3.3 Immunological Disorders
7.3.4 Cardiovascular Disorders
7.3.5 Hematological Disorders
7.3.6 Others
8 Global Biologics Market, By Manufacturing
8.1 Y-o-Y Growth Comparison, By Manufacturing
8.2 Global Biologics Market Share Analysis, By Manufacturing
8.3 Global Biologics Market Size and Forecast, By Manufacturing
8.3.1 Outsourced
8.3.2 In-house
9 Global Biologics Market, By Region
9.1 Global Biologics Market Share Analysis, By Region
9.1 Global Biologics Market Share Analysis, By Region
9.2 Global Biologics Market Size and Forecast, By Region
10 North America Biologics Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 North America Biologics Market Share Analysis, By Source
10.3 North America Biologics Market Share Analysis, By Product
10.4 North America Biologics Market Share Analysis, By Disease Category
10.5 North America Biologics Market Share Analysis, By Manufacturing
10.6 North America Biologics Market Size and Forecast, By Country
10.6.1 U.S
10.6.1.1 Market Size and Forecast, By Source
10.6.1.2 Market Size and Forecast, By Product
10.6.1.3 Market Size and Forecast, By Disease Category
10.6.1.4 Market Size and Forecast, By Manufacturing
10.6.2 Canada
10.6.2.1 Market Size and Forecast, By Source
10.6.2.2 Market Size and Forecast, By Product
10.6.2.3 Market Size and Forecast, By Disease Category
10.6.2.4 Market Size and Forecast, By Manufacturing
10.6.3 Mexico
10.6.3.1 Market Size and Forecast, By Source
10.6.3.2 Market Size and Forecast, By Product
10.6.3.3 Market Size and Forecast, By Disease Category
10.6.3.4 Market Size and Forecast, By Manufacturing
11 Europe Biologics Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Europe Biologics Market Share Analysis, By Source
11.3 Europe Biologics Market Share Analysis, By Product
11.4 Europe Biologics Market Share Analysis, By Disease Category
11.5 Europe Biologics Market Share Analysis, By Manufacturing
11.6 Europe Biologics Market Size and Forecast, By Country
11.6.1 Germany
11.6.1.1 Market Size and Forecast, By Source
11.6.1.2 Market Size and Forecast, By Product
11.6.1.3 Market Size and Forecast, By Disease Category
11.6.1.4 Market Size and Forecast, By Manufacturing
11.6.2 France
11.6.2.1 Market Size and Forecast, By Source
11.6.2.2 Market Size and Forecast, By Product
11.6.2.3 Market Size and Forecast, By Disease Category
11.6.2.4 Market Size and Forecast, By Manufacturing
11.6.3 UK
11.6.3.1 Market Size and Forecast, By Source
11.6.3.2 Market Size and Forecast, By Product
11.6.3.3 Market Size and Forecast, By Disease Category
11.6.3.4 Market Size and Forecast, By Manufacturing
11.6.4 Russia
11.6.4.1 Market Size and Forecast, By Source
11.6.4.2 Market Size and Forecast, By Product
11.6.4.3 Market Size and Forecast, By Disease Category
11.6.4.4 Market Size and Forecast, By Manufacturing
11.6.5 Italy
11.6.5.1 Market Size and Forecast, By Source
11.6.5.2 Market Size and Forecast, By Product
11.6.5.3 Market Size and Forecast, By Disease Category
11.6.5.4 Market Size and Forecast, By Manufacturing
11.6.6 Spain
11.6.6.1 Market Size and Forecast, By Source
11.6.6.2 Market Size and Forecast, By Product
11.6.6.3 Market Size and Forecast, By Disease Category
11.6.6.4 Market Size and Forecast, By Manufacturing
11.6.7 Rest of Europe
11.6.7.1 Market Size and Forecast, By Source
11.6.7.2 Market Size and Forecast, By Product
11.6.7.3 Market Size and Forecast, By Disease Category
11.6.7.4 Market Size and Forecast, By Manufacturing
12 Asia Pacific Biologics Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Asia-Pacific Biologics Market Share Analysis, By Source
12.3 Asia-Pacific Biologics Market Share Analysis, By Product
12.4 Asia-Pacific Biologics Market Share Analysis, By Disease Category
12.5 Asia-Pacific Biologics Market Share Analysis, By Manufacturing
12.6 Asia-Pacific Biologics Market Share Analysis, By Country
12.6.1 China
12.6.1.1 Market Size and Forecast, By Source
12.6.1.2 Market Size and Forecast, By Product
12.6.1.3 Market Size and Forecast, By Disease Category
12.6.1.4 Market Size and Forecast, By Manufacturing
12.6.2 Japan
12.6.2.1 Market Size and Forecast, By Source
12.6.2.2 Market Size and Forecast, By Product
12.6.2.3 Market Size and Forecast, By Disease Category
12.6.2.4 Market Size and Forecast, By Manufacturing
12.6.3 India
12.6.3.1 Market Size and Forecast, By Source
12.6.3.2 Market Size and Forecast, By Product
12.6.3.3 Market Size and Forecast, By Disease Category
12.6.3.4 Market Size and Forecast, By Manufacturing
12.6.4 South Korea
12.6.4.1 Market Size and Forecast, By Source
12.6.4.2 Market Size and Forecast, By Product
12.6.4.3 Market Size and Forecast, By Disease Category
12.6.4.4 Market Size and Forecast, By Manufacturing
12.6.5 Australia
12.6.5.1 Market Size and Forecast, By Source
12.6.5.2 Market Size and Forecast, By Product
12.6.5.3 Market Size and Forecast, By Disease Category
12.6.5.4 Market Size and Forecast, By Manufacturing
12.6.6 Newzealand
12.6.6.1 Market Size and Forecast, By Source
12.6.6.2 Market Size and Forecast, By Product
12.6.6.3 Market Size and Forecast, By Disease Category
12.6.6.4 Market Size and Forecast, By Manufacturing
12.6.7 Singapore
12.6.7.1 Market Size and Forecast, By Source
12.6.7.2 Market Size and Forecast, By Product
12.6.7.3 Market Size and Forecast, By Disease Category
12.6.7.4 Market Size and Forecast, By Manufacturing
12.6.8 Malaysia
12.6.8.1 Market Size and Forecast, By Source
12.6.8.2 Market Size and Forecast, By Product
12.6.8.3 Market Size and Forecast, By Disease Category
12.6.8.4 Market Size and Forecast, By Manufacturing
12.8.9. Rest of Asia Pacific
12.6.9.1 Market Size and Forecast, By Source
12.6.9.2 Market Size and Forecast, By Product
12.6.9.3 Market Size and Forecast, By Disease Category
12.6.9.4 Market Size and Forecast, By Manufacturing
13 Latin America Biologics Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Latin America Biologics Market Share Analysis, By Source
13.3 Latin America Biologics Market Share Analysis, By Product
13.4 Latin America Biologics Market Share Analysis, By Disease Category
13.5 Latin America Biologics Market Share Analysis, By Manufacturing
13.6 Latin America Biologics Market Size and Forecast, By Country
13.6.1 Brazil
13.6.1.1 Market Size and Forecast, By Source
13.6.1.2 Market Size and Forecast, By Product
13.6.1.3 Market Size and Forecast, By Disease Category
13.6.1.4 Market Size and Forecast, By Manufacturing
13.6.2. Malaysia
13.6.2.1 Market Size and Forecast, By Source
13.6.2.2 Market Size and Forecast, By Product
13.6.2.3 Market Size and Forecast, By Disease Category
13.6.2.4 Market Size and Forecast, By Manufacturing
13.6.3 Colombia
13.6.3.1 Market Size and Forecast, By Source
13.6.3.2 Market Size and Forecast, By Product
13.6.3.3 Market Size and Forecast, By Disease Category
13.6.3.4 Market Size and Forecast, By Manufacturing
13.6.4 Peru
13.6.4.1 Market Size and Forecast, By Source
13.6.4.2 Market Size and Forecast, By Product
13.6.4.3 Market Size and Forecast, By Disease Category
13.6.4.4 Market Size and Forecast, By Manufacturing
13.6.5 Chile
13.6.5.1 Market Size and Forecast, By Source
13.6.5.2 Market Size and Forecast, By Product
13.6.5.3 Market Size and Forecast, By Disease Category
13.6.5.4 Market Size and Forecast, By Manufacturing
14 Middle East Biologics Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Middle East Biologics Market Share Analysis, By Source
14.3 Middle East Biologics Market Share Analysis, By Product
14.4 Middle East Biologics Market Share Analysis, By Disease Category
14.5 Middle East Biologics Market Share Analysis, By Manufacturing
14.6 Middle East Biologics Market Share Analysis, By Country
14.6.1. Saudi Arabia
14.6.1.1 Market Size and Forecast, By Source
14.6.1.2 Market Size and Forecast, By Product
14.6.1.3 Market Size and Forecast, By Disease Category
14.6.1.4 Market Size and Forecast, By Manufacturing
14.6.2. UAE
14.6.2.1 Market Size and Forecast, By Source
14.6.2.2 Market Size and Forecast, By Product
14.6.2.3 Market Size and Forecast, By Disease Category
14.6.2.4 Market Size and Forecast, By Manufacturing
14.6.3. Egypt
13.6.3.1 Market Size and Forecast, By Source
13.6.3.2 Market Size and Forecast, By Product
13.6.3.3 Market Size and Forecast, By Disease Category
13.6.3.4 Market Size and Forecast, By Manufacturing
14.6.4. Kuwait
14.6.4.1 Market Size and Forecast, By Source
14.6.4.2 Market Size and Forecast, By Product
14.6.4.3 Market Size and Forecast, By Disease Category
14.6.4.4 Market Size and Forecast, By Manufacturing
14.6.5. South Africa
14.6.4.1 Market Size and Forecast, By Source
14.6.4.2 Market Size and Forecast, By Product
14.6.4.3 Market Size and Forecast, By Disease Category
14.6.4.4 Market Size and Forecast, By Manufacturing
14.6.6 Venezuela
14.6.4.1 Market Size and Forecast, By Source
14.6.4.2 Market Size and Forecast, By Product
14.6.4.3 Market Size and Forecast, By Disease Category
14.6.4.4 Market Size and Forecast, By Manufacturing
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1. Eli Lilly & Company
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2. Samsung Biologics
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3. F Hoffman La Roche
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4. Celltrion
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5. Addgene
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6. Amgen
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7. Abbvie Inc
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8. Sanofi
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9. Pfizer Inc
16.9.1 Overview
16.9.2 Offerings
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5Key Market Developments
16.9.6 Key Strategies
16.10. Merck & Co Inc
16.10.1 Overview
16.10.2 Offerings
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies
16.11. Novo Nordisk A/S
16.11.1 Overview
16.11.2 Offerings
16.11.3 Key Financials
16.11.4 Business Segment & Geographic Overview
16.11.5 Key Market Developments
16.11.6 Key Strategies
16.12. Johnson & Johnson Services Inc
16.12.1 Overview
16.12.2 Offerings
16.12.3 Key Financials
16.12.4 Business Segment & Geographic Overview
16.12.5 Key Market Developments
16.12.6 Key Strategies
